Sugi Predict

Sugi Predict / Compounds / SCHEMBL786095

SCHEMBL786095

SCHEMBL786095

Nc1n[nH]c2c(F)cc(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.40
▸ CHEK1 O14757 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ PLK3 Q9H4B4 1/20 0.37
▸ MAP4K4 O95819 2/20 0.34
▸ CSF1R P07333 2/20 0.34
▸ FGFR1 P11362 2/20 0.34
▸ LTK P29376 2/20 0.34
▸ KDR P35968 2/20 0.34
▸ MAPK8 P45983 2/20 0.34
▸ CSNK1A1 P48729 2/20 0.34
▸ CDK5 Q00535 2/20 0.34
▸ ACVR1 Q04771 2/20 0.34
▸ TNK2 Q07912 2/20 0.34
▸ CLK4 Q9HAZ1 2/20 0.34
▸ DYRK1B Q9Y463 2/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ LIMK1 P53667 1/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ JAK2 O60674 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13122194 0.78 ADORA2A (0.49) GPR84CDK5EGFRARALDH1A1
SCHEMBL19249596 0.78 GPR84 (0.39) GPR84EGFRARDAO
SCHEMBL19255693 0.75 EGFR (0.31) EGFRMAPK14SGK1
SCHEMBL15081372 0.73 CCNE2 (0.38) CYP3A4MEN1MAPTKMT2AALDH1A1
SCHEMBL30536600 0.73 GPR84 (0.36) GPR84EGFR
SCHEMBL786302 0.71 CHEK1 (0.60) GPR84CHEK1FLT3PLK3MAP4K4
SCHEMBL16680979 0.69 MAP4K4 (0.44) FLT3MAP4K4CSF1RFGFR1LTK
SCHEMBL31411344 0.69 MPO (0.39) GPR84AR
SCHEMBL6490868 0.68 PDPK1 (0.39) CHEK1FLT3PLK3MAP4K4CSF1R
SCHEMBL28706409 0.67 GPR84 (0.48) GPR84ARALDH1A1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259241-A1 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF Transneural Therapeutics, Inc. (US) 2024-12-19 — — WO disclosed
EP-3609883-B1 FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-06-29 — — EP disclosed
US-11242335-B2 Fluorine-substituted indazole compounds and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-02-08 — — US disclosed
US-20210101882-A1 FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-08 — — US disclosed
CN-108727340-B Fluorine substituted indazoles and use thereof 广东东阳光药业有限公司 2020-12-29 — — CN disclosed
WO-2017133664-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 — — WO disclosed
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 — — US disclosed
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 — — US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 — — US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 — — US disclosed
US-20030064981-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-04-03 — — US disclosed
US-20030064982-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-04-03 — — US disclosed
US-20030055044-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-03-20 — — US disclosed
WO-2002022603-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022602-A2 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022608-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022604-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022605-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022606-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed
WO-2002022601-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064981-A1 Pyrazole compounds useful as protein kinase inhibitors AURKC, AURKA, GSK3A GPR84 3597/4885CHEK1 72/4885FLT3 977/4885
US-20030064982-A1 Pyrazole compounds useful as protein kinase inhibitors MAP3K20, CDK2, MAP2K2 GPR84 2719/4885CHEK1 207/4885FLT3 1041/4885
US-20030055044-A1 Pyrazole compounds useful as protein kinase inhibitors AURKC, AURKA, GSK3B GPR84 3254/4885CHEK1 72/4885FLT3 1048/4885
US-11242335-B2 Fluorine-substituted indazole compounds and uses thereof GUCY1B2, GUCY1A2, PDE3A GPR84 457/4885CHEK1 806/4885FLT3 129/4885
US-20210101882-A1 FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF PDE3A, PDE3B, PDE5A GPR84 307/4885CHEK1 1128/4885FLT3 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.